Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note released on Monday morning,Benzinga reports. They currently have a $40.00 price target on the stock.

DNTH has been the subject of a number of other research reports. Wedbush raised their target price on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. William Blair initiated coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an “outperform” rating for the company. Finally, Robert W. Baird lowered their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $54.00.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $31.80 on Monday. The firm has a market cap of $1.02 billion, a PE ratio of -9.78 and a beta of 1.46. The business’s 50 day simple moving average is $21.54 and its 200 day simple moving average is $20.09. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $32.80.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNTH. Vestal Point Capital LP increased its position in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. lifted its position in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after buying an additional 1,000,333 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in shares of Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after acquiring an additional 363,500 shares during the period. Candriam S.C.A. acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $4,510,000. Finally, Alliancebernstein L.P. raised its stake in Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after acquiring an additional 149,200 shares during the period. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.